BWC Antibiogram 2025

GRAM NEGATIVE	ANTIBIOTICS															
1/1/2025-12/31/2025	Number tested	Amoxicillin/Clavulanic Acid	Ampicillin	Cefazolin	Cefepime	Ceftriaxone	Ciprofloxacin	Ertapenem	Gentamicin [a]	Levofloxacin	Meropenem	Nitrofurantoin [c]	Piperacillin/Tazobactam	Tetracycline	Tobramycin [a]	Trimeth/Sulfa
ORGANISM	**PERCENT SUSCEPTIBLE**															
Enterobacter cloacae complex	41	•		•	90	•	80		100	83	90	39	•			80
Escherichia coli	654	84		84	93	89	70	#	93	71	100	95	97			74
Escherichia coli (urine only, ED)	158	83		85	94	92	73	#	91	73	100	97	97			80
Klebsiella pneumoniae	163	93		85	91	88	82	#	95	83	98	30	93			86
Proteus mirabilis	76	88		93	100	99	91	#	96	91	100	0	100			87
Pseudomonas aeruginosa	127				90		76			71	87		86			

GRAM POSITIVE	ANTIBIOTICS											
1/1/2025-12/31/2025	Number tested	Ampicillin	Clindamycin	Erythromycin	Gentamycin (High-Level)	Linezolid	Nitrofurantoin [c]	Oxacillin	Streptomycin (High-Level)	Tetracycline	Trimeth/Sulfa	Vancomycin
Organism	**PERCENT SUSCEPTIBLE**											
Enterococcus faecalis	122	99			81	98	98		88	23		99
Staphylococcus aureus, ALL	164		66	40		100		66		87	93	100
MRSA only	52		69	17		100		0		81	85	100
MSSA only	112		69	56		100		100		91	99	100
Staphylococcus epidermidis	70		66	34		100		39		76	59	100

85-100% Susceptible
60-84% Susceptible
<60% Susceptible
Not routinely tested. Historical data suggests frequent susceptibility; confirm with microbiology when relevant
• Due to the presence of inducible beta-lactamases, this organism should be considered resistant to the antimicrobial indicated
Shaded boxes indicate organism/antimicrobial combinates not tested routinely

(a) Data with fewer than 30 isolates has poor statistical validity.
(b) Aminoglycoside breakpoints were lowered in 2023 for Enterobacterales and Pseudomonas aeruginosa. Gentamicin should no longer be used for the treatment of Pseudomonas aeruginosa infections.
(c) Nitrofurantoin should only be used for infections localized to the bladder only.